Meeting News Coverage

Novel treatment to prevent vein graft failure confers improved outcomes after CABG

A vascular graft treatment improved long-term outcomes in patients who underwent CABG, according to results of the MAVERIC study.

Researchers conducted a retrospective, nonrandomized real-world study of 2,436 patients who had CABG with at least one saphenous vein graft. In the cohort, 1,036 were treated with the vascular graft treatment designed to protect the endothelial function of the conduit (DuraGraft, Somahlution) and 1,400 had standard-of-care CABG.

Mean follow-up was 7.2 years in the treatment group and 7.7 years in the standard group. Miguel Haime, MD, from the VA Boston Healthcare System and Harvard Medical School, presented results at the European Association for Cardio-Thoracic Surgery Annual Meeting.

The treatment group had lower risk for nonfatal MI, which began at 30 days (adjusted HR = 0.64; 95% CI, 0.5-0.82) and was most evident starting at 1,000 days (adjusted HR = 0.5; 95% CI, 0.35-0.71), Haime said during a presentation.

At 1,000 days, the treatment was associated with reduced risk for repeat revascularization (adjusted HR = 0.62; 95% CI, 0.41-0.96) and major adverse CV events (adjusted HR = 0.71; 95% CI, 0.53-0.95), according to the researchers.

There was no difference between the groups in long-term mortality.

“These new findings highlight that the protective effects of the DuraGraft treatment present significant advantages in long-term clinical follow-up post-CABG,” Haime said in a press release. “These results provide further supporting evidence indicating the importance of graft treatment during surgery and its potentially significant role in reducing graft failure for thousands of CABG patients each year.”

The treatment is not yet available for commercial use in the United States. – by Erik Swain

Reference:

Haime M, et al. Coronary artery bypass graft: Decreasing complications and improving graft potency. Presented at: European Association for Cardio-Thoracic Surgery Annual Meeting; Oct. 1-5, 2016; Barcelona, Spain.

Disclosure: Haime reports no relevant financial disclosures.

 

 

A vascular graft treatment improved long-term outcomes in patients who underwent CABG, according to results of the MAVERIC study.

Researchers conducted a retrospective, nonrandomized real-world study of 2,436 patients who had CABG with at least one saphenous vein graft. In the cohort, 1,036 were treated with the vascular graft treatment designed to protect the endothelial function of the conduit (DuraGraft, Somahlution) and 1,400 had standard-of-care CABG.

Mean follow-up was 7.2 years in the treatment group and 7.7 years in the standard group. Miguel Haime, MD, from the VA Boston Healthcare System and Harvard Medical School, presented results at the European Association for Cardio-Thoracic Surgery Annual Meeting.

The treatment group had lower risk for nonfatal MI, which began at 30 days (adjusted HR = 0.64; 95% CI, 0.5-0.82) and was most evident starting at 1,000 days (adjusted HR = 0.5; 95% CI, 0.35-0.71), Haime said during a presentation.

At 1,000 days, the treatment was associated with reduced risk for repeat revascularization (adjusted HR = 0.62; 95% CI, 0.41-0.96) and major adverse CV events (adjusted HR = 0.71; 95% CI, 0.53-0.95), according to the researchers.

There was no difference between the groups in long-term mortality.

“These new findings highlight that the protective effects of the DuraGraft treatment present significant advantages in long-term clinical follow-up post-CABG,” Haime said in a press release. “These results provide further supporting evidence indicating the importance of graft treatment during surgery and its potentially significant role in reducing graft failure for thousands of CABG patients each year.”

The treatment is not yet available for commercial use in the United States. – by Erik Swain

Reference:

Haime M, et al. Coronary artery bypass graft: Decreasing complications and improving graft potency. Presented at: European Association for Cardio-Thoracic Surgery Annual Meeting; Oct. 1-5, 2016; Barcelona, Spain.

Disclosure: Haime reports no relevant financial disclosures.